Summary
• Sangamo Therapeutics’ stock rose 7.5% in pre-market trading following positive Q3 financial results and FDA discussions regarding accelerated approval for a Fabry disease treatment.
• The company reaffirmed its FDA agreement to use eGFR slope as a key endpoint and showcased promising clinical data from its STAAR study.
• Barclays downgraded Sangamo’s analyst rating from “Overweight” to “Equal-Weight,” significantly lowering the price target from $5 to $1 amid ongoing revenue challenges and a 73% decline in stock value over the past year.
Sangamo Therapeutics, Inc. (SGMO) is up 7.5% in pre-market trading, reaching a price of $0.4528 compared to the last close of $0.4213. This shift comes after the company reported significant updates in their third-quarter financial results and clinical developments, including discussions with the FDA.
Business Highlights Support Price Movement
On November 6, Sangamo announced its recent business highlights alongside its third-quarter financial results. A key point was the reaffirmation of an agreement with the FDA to utilize estimated glomerular filtration rate (eGFR) slope as an endpoint for the accelerated approval path of isaralgagene civaparvovec in treating Fabry disease. The company also presented detailed clinical data from its STAAR study, indicating the potential for isaralgagene civaparvovec to offer significant, long-term benefits beyond current treatment standards.
Analyst Rating Update
Following the earnings release, Barclays downgraded Sangamo’s analyst rating from “Overweight” to “Equal-Weight.” The price target was significantly reduced from $5 to $1. This shift in sentiment may suggest caution regarding the company’s near-term growth prospects, which investors will likely weigh against the positive developments announced.
Financial Overview
Sangamo reported a substantial earnings surprise with a current actual EPS of -$0.11 versus an estimated -$0.03, marking a 267% surprise. For the fiscal quarter ending September 30, the revenue estimates stood at approximately $34.4 million, although specific figures were not disclosed. The company has seen a decline of around 73% in stock value over the past year, indicating ongoing challenges.
Market and Technical Picture
As of now, SGMO is exhibiting a significant volatility profile, with an average trading volume of 4.1 million over the past ten days. The Relative Strength Index (RSI) stands at 30.15, indicating potential oversold conditions, while the stock is trading well below historical moving averages: -21.7% from the 20-day SMA, -28.5% from the 50-day SMA, and -35.8% from the 200-day SMA. Over the past month, shares have dipped 36.2%, though a quarterly performance rebound of 7.1% may indicate a budding recovery phase.
With today’s significant pre-market advancement, investor attention is likely shifting towards the company’s strategic directions and future potentials following recent announcements.